[{"id":"867a967c-2649-4257-8315-9ba87b5b16ef","acronym":"ENGAGE","url":"https://clinicaltrials.gov/study/NCT03776071","created_at":"2021-01-18T18:40:48.140Z","updated_at":"2024-07-02T16:35:08.333Z","phase":"Phase 3","brief_title":"A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1","source_id_and_acronym":"NCT03776071 - ENGAGE","lead_sponsor":"Denovo Biopharma LLC","biomarkers":" MGMT","pipe":" | ","alterations":" MGMT promoter methylation","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Kinenza (enzastaurin)"],"overall_status":"Completed","enrollment":" Enrollment 260","initiation":"Initiation: 12/16/2020","start_date":" 12/16/2020","primary_txt":" Primary completion: 02/29/2024","primary_completion_date":" 02/29/2024","study_txt":" Completion: 02/29/2024","study_completion_date":" 02/29/2024","last_update_posted":"2024-04-22"},{"id":"06720a94-afad-45b5-b723-829be3f96dec","acronym":"","url":"https://clinicaltrials.gov/study/NCT03263026","created_at":"2021-01-18T16:07:07.298Z","updated_at":"2024-07-02T16:36:06.322Z","phase":"Phase 3","brief_title":"Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™","source_id_and_acronym":"NCT03263026","lead_sponsor":"Denovo Biopharma LLC","biomarkers":" BCL2 • CD20 • BCL6","pipe":" | ","alterations":" CD20 positive • BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • CD20 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Kinenza (enzastaurin)"],"overall_status":"Completed","enrollment":" Enrollment 256","initiation":"Initiation: 03/20/2018","start_date":" 03/20/2018","primary_txt":" Primary completion: 07/12/2022","primary_completion_date":" 07/12/2022","study_txt":" Completion: 07/12/2022","study_completion_date":" 07/12/2022","last_update_posted":"2022-08-01"},{"id":"0a63c4b1-161e-4ca3-850e-3f6745c84eb4","acronym":"","url":"https://clinicaltrials.gov/study/NCT00542919","created_at":"2021-01-29T06:57:45.928Z","updated_at":"2024-07-02T16:36:39.920Z","phase":"Phase 2","brief_title":"A Study for Patients With Non-Hodgkin's Lymphomas","source_id_and_acronym":"NCT00542919","lead_sponsor":"Eli Lilly and Company","biomarkers":" CD4 • DPP4","pipe":"","alterations":" ","tags":["CD4 • DPP4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kinenza (enzastaurin)"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 11/01/2007","start_date":" 11/01/2007","primary_txt":" Primary completion: 03/01/2010","primary_completion_date":" 03/01/2010","study_txt":" Completion: 02/27/2018","study_completion_date":" 02/27/2018","last_update_posted":"2020-10-19"},{"id":"e5f2912b-4e70-4d16-a5ef-71f099ef4b42","acronym":"","url":"https://clinicaltrials.gov/study/NCT00391118","created_at":"2021-01-18T01:21:52.062Z","updated_at":"2024-07-02T16:36:39.969Z","phase":"Phase 2","brief_title":"Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo (\"Sugar Pill\")","source_id_and_acronym":"NCT00391118","lead_sponsor":"Eli Lilly and Company","biomarkers":" PTEN • MUC16 • GSK3B • PRKCB","pipe":"","alterations":" ","tags":["PTEN • MUC16 • GSK3B • PRKCB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • Kinenza (enzastaurin)"],"overall_status":"Completed","enrollment":" Enrollment 153","initiation":"Initiation: 11/01/2006","start_date":" 11/01/2006","primary_txt":" Primary completion: 04/01/2010","primary_completion_date":" 04/01/2010","study_txt":" Completion: 07/01/2012","study_completion_date":" 07/01/2012","last_update_posted":"2020-10-19"},{"id":"2b886b25-d61f-4bf9-beb7-aaace50b841c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00042666","created_at":"2021-06-23T22:52:32.202Z","updated_at":"2024-07-02T16:36:42.179Z","phase":"Phase 2","brief_title":"A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.","source_id_and_acronym":"NCT00042666","lead_sponsor":"Eli Lilly and Company","biomarkers":" PRKCB","pipe":"","alterations":" ","tags":["PRKCB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kinenza (enzastaurin)"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 06/01/2002","start_date":" 06/01/2002","primary_txt":" Primary completion: 09/01/2008","primary_completion_date":" 09/01/2008","study_txt":" Completion: 09/01/2008","study_completion_date":" 09/01/2008","last_update_posted":"2020-08-10"},{"id":"2f391593-66cc-4bb3-adf8-6fa0bb902d02","acronym":"","url":"https://clinicaltrials.gov/study/NCT00192114","created_at":"2021-01-18T00:39:09.481Z","updated_at":"2024-07-02T16:36:42.276Z","phase":"Phase 2","brief_title":"Enzastaurin for Patients With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT00192114","lead_sponsor":"Eli Lilly and Company","biomarkers":" CEACAM5","pipe":"","alterations":" ","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kinenza (enzastaurin)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 08/01/2005","start_date":" 08/01/2005","primary_txt":" Primary completion: 03/01/2008","primary_completion_date":" 03/01/2008","study_txt":" Completion: 03/01/2008","study_completion_date":" 03/01/2008","last_update_posted":"2020-08-06"},{"id":"370e6b2e-796f-4e1b-a0c3-f76e727397f4","acronym":"","url":"https://clinicaltrials.gov/study/NCT00436280","created_at":"2021-01-18T01:32:22.047Z","updated_at":"2024-07-02T16:36:42.265Z","phase":"Phase 2","brief_title":"Chemotherapy for Participants With Lymphoma","source_id_and_acronym":"NCT00436280","lead_sponsor":"Eli Lilly and Company","biomarkers":" CD20 • PRKCH • PRKCB","pipe":"","alterations":" ","tags":["CD20 • PRKCH • PRKCB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Rituxan (rituximab) • oxaliplatin • Kinenza (enzastaurin)"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 02/01/2007","start_date":" 02/01/2007","primary_txt":" Primary completion: 11/01/2009","primary_completion_date":" 11/01/2009","study_txt":" Completion: 11/01/2012","study_completion_date":" 11/01/2012","last_update_posted":"2020-08-06"},{"id":"0a7b2fa7-a40c-474b-8236-37798e0d2949","acronym":"","url":"https://clinicaltrials.gov/study/NCT00088205","created_at":"2021-01-18T00:15:39.042Z","updated_at":"2024-07-02T16:36:43.664Z","phase":"Phase 2","brief_title":"Oral Enzastaurin in Participants With Relapsed Mantle Cell Lymphoma","source_id_and_acronym":"NCT00088205","lead_sponsor":"Eli Lilly and Company","biomarkers":" PRKCH • PRKCB","pipe":"","alterations":" ","tags":["PRKCH • PRKCB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kinenza (enzastaurin)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 03/01/2004","start_date":" 03/01/2004","primary_txt":" Primary completion: 05/01/2008","primary_completion_date":" 05/01/2008","study_txt":" Completion: 05/01/2008","study_completion_date":" 05/01/2008","last_update_posted":"2020-07-01"},{"id":"eb9c561a-7a93-4afa-b544-0a1eeb54d259","acronym":"","url":"https://clinicaltrials.gov/study/NCT00509821","created_at":"2021-07-05T16:01:16.362Z","updated_at":"2024-07-02T16:37:00.837Z","phase":"Phase 2","brief_title":"Enzastaurin Before and Concomitant With Radiation, Followed by Enzastaurin in Participants With Newly Diagnosed Glioblastoma","source_id_and_acronym":"NCT00509821","lead_sponsor":"Eli Lilly and Company","biomarkers":" GSK3B","pipe":"","alterations":" ","tags":["GSK3B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kinenza (enzastaurin)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 10/01/2007","start_date":" 10/01/2007","primary_txt":" Primary completion: 02/01/2010","primary_completion_date":" 02/01/2010","study_txt":" Completion: 03/01/2016","study_completion_date":" 03/01/2016","last_update_posted":"2019-04-05"},{"id":"6462b1e0-4b1c-4573-96bc-10fc5acd50bb","acronym":"","url":"https://clinicaltrials.gov/study/NCT00332202","created_at":"2021-06-23T22:52:36.234Z","updated_at":"2024-07-02T16:37:07.092Z","phase":"Phase 3","brief_title":"PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin","source_id_and_acronym":"NCT00332202","lead_sponsor":"Eli Lilly and Company","biomarkers":" PRKCB • EFS","pipe":"","alterations":" ","tags":["PRKCB • EFS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kinenza (enzastaurin)"],"overall_status":"Completed","enrollment":" Enrollment 758","initiation":"Initiation: 06/01/2006","start_date":" 06/01/2006","primary_txt":" Primary completion: 04/01/2013","primary_completion_date":" 04/01/2013","study_txt":" Completion: 07/01/2013","study_completion_date":" 07/01/2013","last_update_posted":"2018-09-10"}]